Welcome to our dedicated page for Bioqual news (Ticker: BIOQ), a resource for investors and traders seeking the latest updates and insights on Bioqual stock.
BIOQUAL Inc. reports recurring financial results and governance updates as an OTC Pink/Pink Limited public company. Its announcements center on quarterly and annual revenue, income or loss before taxes, net income or loss, earnings per common share, and weighted average shares outstanding.
Company news also documents board and senior leadership changes, including retirements and appointments connected to corporate oversight and BIOQUAL's contract research program.
BIOQUAL (BIOQ) has announced its twenty-third dividend declaration. The company's Board of Directors has declared a dividend of $0.50 per share for shareholders of record on October 7, 2024. The dividend is payable on October 28, 2024.
This announcement demonstrates BIOQUAL's commitment to returning value to its shareholders. The dividend declaration suggests the company's financial stability and confidence in its future performance. However, it's important to note that past performance does not guarantee future results, and investors should consider their individual financial situations before making investment decisions.
BIOQUAL, Inc. (OTC Pink: BIOQ) has released its financial results for Fiscal Year 2024. The company reported:
- Revenue of $58,590,949, down from $62,663,804 in 2023
- Income Before Income Tax of $476,447, compared to $1,133,242 in 2023
- Net Income of $483,481, a decrease from $835,548 in 2023
- Basic and Diluted Earnings per Share of Common Stock both at $0.54, down from $0.93 in 2023
The Weighted Average Number of Shares Outstanding for both Basic and Diluted Earnings Per Share remained constant at 894,416.
BIOQUAL, Inc. (OTC: BIOQ) has announced a 10% reduction in workforce effective September 9, 2024, as a cost-cutting measure in response to decreased revenue and profitability over the past year. The company attributes this decline to a significant drop in demand for its services in the post-COVID-19 environment, following the development of vaccines and therapeutics.
Despite this workforce reduction, BIOQUAL does not anticipate any impact on its current services or future business prospects. The company aims to realign its cost structure to adapt to the changing market conditions while maintaining its operational capabilities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BIOQUAL, Inc. (OTC Pink: BIOQ) reported its unaudited financial results for the third quarter ended February 28, 2023. The company generated revenue of $46.6 million for the nine months, a slight decline from $47.8 million in the previous year. In the third quarter alone, revenue was $14.1 million, compared to $17.1 million in the same period of 2022. The income before tax decreased to $2.17 million from $4.77 million year-over-year, while net income showed a decrease to $1.54 million from $3.37 million. Basic earnings per share (EPS) fell to $1.72 from $3.77, with diluted EPS also declining to $1.72 from $3.77. The company faces ongoing challenges including reliance on government contracts and the need for sufficient animal models.
BIOQUAL, Inc. (OTC-Pink:BIOQ) reported its unaudited second quarter results for fiscal year 2023. For the six months ended November 30, 2022, the company generated revenues of $32.49 million, an increase from $30.67 million in the same period last year. Net income rose to $2.68 million, up from $2.52 million in 2021. Basic earnings per share were $2.99, compared to $2.81 in the prior year. The results reflect the company’s solid performance and increasing demand for its animal models in scientific research. Forward-looking statements highlight potential risks related to government contracts and market demand.